admin – Page 3564 – Get News Story

Royal Chess Mall on Art vs. Function: What Makes a Chess Set Truly Timeless?

For millennia, chess has been a game of strategy, intelligence, and grace. But when it comes to the chess set itself, the question often arises: What makes a chess set truly timeless? Is it its artistic beauty or its functional design? Royal Chess Mall, a well-known manufacturer of handmade wooden chess sets, feels the solution lies in the perfect balance of both parts.

Royal Chess Mall mixes traditional craftsmanship with contemporary design to make chess sets that meet the practical demands of serious players as well as collectors. The artists of Royal Chess Mall have over 40 years of expertise and skillfully carve each chess set from quality materials such as ebony, rosewood, boxwood, and sheesham. As a consequence, the chess set is both highly playable and visually appealing.

“At Royal Chess Mall, we work hard to make chess sets that motivate players and enhance the beauty of the game itself,” says Royal Chess Mall Director Sidharth Kapoor. ”Instead of viewing art and function as opposing ideas, we think they ought to collaborate to produce something genuinely remarkable.”

The company’s range is extensive, ranging from professional-grade Staunton sets used in international tournaments to carefully crafted luxury sets used as display pieces by chess lovers and interior designers. While practicality is important for professional players, collectors value the handmade details and historical relevance of chess pieces. From the masterfully carved knights to the flowing lines of the queens and kings, every piece of art shows the ability and love of the creators.

The commitment to quality at Royal Chess Mall goes beyond craftsmanship. The firm is also heavily focused on sustainability and ethical sourcing. Every piece of wood used in its sets is carefully sourced, guaranteeing that the company’s goods have a low environmental effect.

In order to interact with its worldwide chess community, Royal Chess Mall is seeking players and collectors to give their perspectives on the continuing debate between art and utility. The business hopes to spark a discourse about the balance of form and playability in a timeless chess set via blogs, social media conversations, and consumer feedback.

With distribution centers in the US, UK, Germany, and India, as well as consumers in over 70 countries, Royal Chess Mall has established itself as a trusted brand among both chess pros and enthusiasts.

“Whether you are playing a casual game or showcasing your collection, a truly timeless chess set is one that perfectly balances art and function,” he says.

Media Contact
Company Name: Royal Chess Mall
Contact Person: Sidharth Kapoor
Email: Send Email
City: Claymont
State: DE
Country: United States
Website: royalchessmall.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Royal Chess Mall on Art vs. Function: What Makes a Chess Set Truly Timeless?

The Kugel Law Firm Highlights the Evolution of Drunk Driving Laws

Drinking and driving laws have changed significantly over the past century, shaping how states like New York and New Jersey enforce DWI and DUI charges today. The Kugel Law Firm, with offices in both states, provides an in-depth look into the evolution of these laws and the ongoing challenges they present for individuals charged with impaired driving. From the earliest legislation in the early 1900s to today’s strict enforcement standards, the development of drunk driving laws reflects growing public concern and legal accountability.

Attorney Rachel Kugel (https://thekugellawfirm.com/when-did-drinking-and-driving-become-illegal/) of The Kugel Law Firm explains that the roots of drunk driving regulation began over a century ago, when states first began responding to the dangers of intoxicated driving. “The first DUI laws relied entirely on physical observation—there were no BAC tests or standardized tools,” Kugel notes. In New Jersey, drunk driving was criminalized as early as 1906, while New York followed closely in 1910 with one of the nation’s first formal statutes. The role of a New Jersey DUI lawyer was far less defined in those days, as courts often struggled to enforce vague or subjective laws.

By the 1930s, enforcement still lacked consistency, which made the work of a New York DWI lawyer or New Jersey DUI lawyer especially challenging. Scientific advances helped fill that gap. Devices like the Drunkometer, introduced in 1936, and the Breathalyzer in 1953, marked key turning points in the ability of law enforcement to reliably test drivers. The Kugel Law Firm emphasizes that “these breakthroughs provided a more objective standard for determining intoxication,” which helped move the legal system toward greater fairness and accountability.

Rachel Kugel explains that enforcement remained inconsistent throughout the mid-20th century. Though laws existed on the books, public attitudes toward impaired driving were often lenient. Juries hesitated to convict drivers unless severe harm had occurred. This disconnect led to increased efforts in the 1970s and 1980s to shift public perception and create uniform standards across all states. Both New York and New Jersey responded by lowering BAC limits and increasing penalties for offenders. Advocacy groups like Mothers Against Drunk Driving (MADD) were instrumental in pushing for tougher laws and changing how society viewed drunk driving.

The 1980s were a pivotal decade for DUI enforcement, and lawyers like Rachel Kugel saw firsthand how new legal frameworks developed. Federal legislation, such as the National Minimum Drinking Age Act of 1984, prompted states to adopt stricter measures in order to qualify for highway funding. New Jersey, already a leader in DUI regulation, aligned with these standards by reinforcing its legal thresholds and penalties. New York followed suit by implementing tougher laws, including the introduction of aggravated DWI charges for drivers with a BAC of 0.18% or higher.

Today, both states maintain strict enforcement protocols. In New Jersey, drivers can be charged with DWI for a BAC of 0.08% or higher, with no distinction between DUI and DWI in state statutes. Rachel Kugel points out that “New Jersey treats DWI as a traffic offense rather than a criminal charge, but the consequences are serious—jail time, license suspension, and mandatory ignition interlock devices.” Repeat offenders face even harsher penalties, with third-time offenses resulting in eight-year license suspensions and mandatory jail time.

New York law also sets a BAC threshold of 0.08% for DWI, but includes additional categories such as Driving While Ability Impaired (DWAI) for BACs between 0.05% and 0.07%. The state has further expanded penalties for aggravated offenses and repeat violations. Leandra’s Law, enacted in New York, imposes felony charges on anyone caught driving drunk with a child passenger, even on a first offense.

Commercial drivers and underage drivers face stricter regulations in both states. A BAC of 0.04% can result in penalties for commercial vehicle operators, while anyone under 21 is subject to zero-tolerance laws—often triggered by a BAC as low as 0.01% in New Jersey or 0.02% in New York.

According to Rachel Kugel, the shift toward preventative measures has also changed the way courts handle sentencing. “Many states, including New Jersey, now prioritize ignition interlock devices over lengthy license suspensions to reduce the risk of repeat offenses,” she says. These changes are part of a broader trend toward using technology and data to address the persistent problem of impaired driving.

Despite progress, challenges remain. Drunk driving continues to account for around 30% of all traffic-related fatalities in the United States. Hardcore repeat offenders, often with high BAC levels, are involved in a disproportionate number of fatal crashes. In response, states have considered lowering BAC limits even further and introducing vehicle-integrated alcohol detection systems to prevent intoxicated individuals from starting their cars.

For those facing DWI or DUI charges in New York or New Jersey, The Kugel Law Firm provides strong legal defense and guidance. The firm’s commitment to protecting the rights of the accused reflects a deep understanding of the historical and current legal landscape. With a focus on challenging evidence and helping clients navigate complex court procedures, Rachel Kugel and her team remain a trusted resource for those seeking to defend themselves against serious charges.

Drivers in New York or New Jersey who are charged with DWI or DUI should act quickly to understand their legal options. The penalties can be severe and long-lasting, affecting driving privileges, employment, and even freedom. The Kugel Law Firm encourages anyone facing such charges to seek legal counsel immediately to ensure their rights are protected and every defense avenue is explored.

About The Kugel Law Firm:

The Kugel Law Firm, led by attorney Rachel Kugel, provides legal defense for individuals charged with drunk driving offenses in New York and New Jersey. With a focus on DWI and DUI cases, the firm works to defend clients’ rights and offer support throughout the legal process.

Embeds:

Youtube Video: https://www.youtube.com/watch?v=Huk38M9-Fhc

GMB: https://www.google.com/maps?cid=17189431107850367088

Email and website

Email: admin@thekugellawfirm.com

Website: https://thekugellawfirm.com/new-york-dwi-lawyer/

Media Contact
Company Name: The Kugel Law Firm
Contact Person: Rachel Kugel
Email: Send Email
Phone: (212) 372-7218
Address:111 E 125th St 2nd Fl
City: New York
State: New York 10035
Country: United States
Website: https://thekugellawfirm.com/new-york-dwi-lawyer/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Kugel Law Firm Highlights the Evolution of Drunk Driving Laws

Post-operative Cataract Surgery Inflammation Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Mallinckrodt Pharma, Salix Pharma, GlaxoSmithKline, Pfizer Inc.

The Key Post-operative Cataract Surgery Inflammation Companies in the market include – Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical, Merck & Co., Inc., Oculis, Formosa Pharmaceuticals, AimMaxTherapeutics, Salvat Laboratories, Azidus Brasil, Bausch & Lomb Incorporated, Laboratorios Poen, Oculis, Alcon Research, and others.

DelveInsight’s “Post-operative Cataract Surgery Inflammation Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Post-operative Cataract Surgery Inflammation, historical and forecasted epidemiology as well as the Post-operative Cataract Surgery Inflammation market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Post-operative Cataract Surgery Inflammation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post-operative Cataract Surgery Inflammation Market Forecast

Some of the key facts of the Post-operative Cataract Surgery Inflammation Market Report:

The Post-operative Cataract Surgery Inflammation market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In December 2024, VivaVision Biotech, a clinical-stage, privately owned biotechnology company dedicated to developing therapies for ocular diseases, today revealed positive topline results from its U.S. Phase 2 clinical trial of VVN461-CS-201. This potent non-steroidal dual JAK1/TYK2 immunomodulator is being developed to treat post-operative inflammation following cataract surgery.
In December 2024, VivaVision Biotech, based in China, plans to move forward with its non-steroidal therapy, VVN461-CS-201 (VVN461), into a Phase III trial after the candidate successfully met the primary endpoint in a Phase II U.S. study focused on treating post-operative inflammation following cataract surgery.
There are around 10 million cataract procedures conducted each year to treat the estimated 95 million people who have them worldwide. As a result, cataract surgery is among the most frequently carried out medical treatments worldwide. After cataract surgery, postoperative inflammation is a typical consequence
According to the American Academy of Ophthalmology (2023), more than 24.4 million Americans aged 40 and older have cataracts. About half of all Americans have cataracts by the age of 75
The National Eye Institute (2020) reports that the US had a 17.11% prevalence of cataracts in 2010. More over half of all Americans 80 years of age and older either have cataracts or have undergone cataract surgery
Key Post-operative Cataract Surgery Inflammation Companies: Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Oculis, Formosa Pharmaceuticals, AimMaxTherapeutics, Salvat Laboratories, Azidus Brasil, Bausch & Lomb Incorporated, Laboratorios Poen, Oculis, Alcon Research, and others
Key Post-operative Cataract Surgery Inflammation Therapies: OCS-01, APP13007, SVT15473, Ster, Bromfenac, Difluprednate, OCS-01 – Dexamethasone, Nepafenac Ophthalmic Suspension, and others
The Post-operative Cataract Surgery Inflammation epidemiology based on gender analyzed that females were more affected by cataract than men
The Post-operative Cataract Surgery Inflammation market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post-operative Cataract Surgery Inflammation pipeline products will significantly revolutionize the Post-operative Cataract Surgery Inflammation market dynamics.

Post-operative Cataract Surgery Inflammation Overview

A cataract is a clouded spot in the eye’s lens, which is clear and helps to concentrate light. Cataracts are quite frequent in older people. In actuality, more than half of all Americans 80 years of age and older either have cataracts or have undergone cataract surgery. Additionally, it is the leading global cause of blindness.

Get a Free sample for the Post-operative Cataract Surgery Inflammation Market Report

https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-market

Post-operative Cataract Surgery Inflammation Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Post-operative Cataract Surgery Inflammation Epidemiology Segmentation:

The Post-operative Cataract Surgery Inflammation market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Post-operative Cataract Surgery Inflammation
Prevalent Cases of Post-operative Cataract Surgery Inflammation by severity
Gender-specific Prevalence of Post-operative Cataract Surgery Inflammation
Diagnosed Cases of Episodic and Chronic Post-operative Cataract Surgery Inflammation

Download the report to understand which factors are driving Post-operative Cataract Surgery Inflammation epidemiology trends @ Post-operative Cataract Surgery Inflammation Epidemiology Forecast

Post-operative Cataract Surgery Inflammation Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-operative Cataract Surgery Inflammation market or expected to get launched during the study period. The analysis covers Post-operative Cataract Surgery Inflammation market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Post-operative Cataract Surgery Inflammation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post-operative Cataract Surgery Inflammation Therapies and Key Companies

OCS-01: Oculis
APP13007: Formosa Pharmaceuticals/AimMaxTherapeutics
SVT15473: Salvat Laboratories
Ster: Azidus Brasil
Bromfenac: Bausch & Lomb Incorporated
Difluprednate: Laboratorios Poen
OCS-01 – Dexamethasone: Oculis
Nepafenac Ophthalmic Suspension: Alcon Research

Discover more about therapies set to grab major Post-operative Cataract Surgery Inflammation market share @ Post-operative Cataract Surgery Inflammation Treatment Market

Post-operative Cataract Surgery Inflammation Market Strengths

Advances in surgical techniques
Advances in the understanding of ophthalmology
Pipeline consists of late and early stage candidates.

Post-operative Cataract Surgery Inflammation Market Opportunities

Uptake of potential emerging therapies with better clinical profile expected to be medium-fast due to the present unmet needs
The side effects associated with therapies currently give a window of opportunity to pharma payer to bring in novel therapies.

Scope of the Post-operative Cataract Surgery Inflammation Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Post-operative Cataract Surgery Inflammation Companies: Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Oculis, Formosa Pharmaceuticals, AimMaxTherapeutics, Salvat Laboratories, Azidus Brasil, Bausch & Lomb Incorporated, Laboratorios Poen, Oculis, Alcon Research, and others
Key Post-operative Cataract Surgery Inflammation Therapies: OCS-01, APP13007, SVT15473, Ster, Bromfenac, Difluprednate, OCS-01 – Dexamethasone, Nepafenac Ophthalmic Suspension, and others
Post-operative Cataract Surgery Inflammation Therapeutic Assessment: Post-operative Cataract Surgery Inflammation current marketed and Post-operative Cataract Surgery Inflammation emerging therapies
Post-operative Cataract Surgery Inflammation Market Dynamics: Post-operative Cataract Surgery Inflammation market drivers and Post-operative Cataract Surgery Inflammation market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Post-operative Cataract Surgery Inflammation Unmet Needs, KOL’s views, Analyst’s views, Post-operative Cataract Surgery Inflammation Market Access and Reimbursement

To know more about Post-operative Cataract Surgery Inflammation companies working in the treatment market, visit @ Post-operative Cataract Surgery Inflammation Clinical Trials and Therapeutic Assessment

Table of Contents

1. Post-operative Cataract Surgery Inflammation Market Report Introduction

2. Executive Summary for Post-operative Cataract Surgery Inflammation

3. SWOT analysis of Post-operative Cataract Surgery Inflammation

4. Post-operative Cataract Surgery Inflammation Patient Share (%) Overview at a Glance

5. Post-operative Cataract Surgery Inflammation Market Overview at a Glance

6. Post-operative Cataract Surgery Inflammation Disease Background and Overview

7. Post-operative Cataract Surgery Inflammation Epidemiology and Patient Population

8. Country-Specific Patient Population of Post-operative Cataract Surgery Inflammation

9. Post-operative Cataract Surgery Inflammation Current Treatment and Medical Practices

10. Post-operative Cataract Surgery Inflammation Unmet Needs

11. Post-operative Cataract Surgery Inflammation Emerging Therapies

12. Post-operative Cataract Surgery Inflammation Market Outlook

13. Country-Wise Post-operative Cataract Surgery Inflammation Market Analysis (2019–2032)

14. Post-operative Cataract Surgery Inflammation Market Access and Reimbursement of Therapies

15. Post-operative Cataract Surgery Inflammation Market Drivers

16. Post-operative Cataract Surgery Inflammation Market Barriers

17. Post-operative Cataract Surgery Inflammation Appendix

18. Post-operative Cataract Surgery Inflammation Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Post-operative Cataract Surgery Inflammation Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Mallinckrodt Pharma, Salix Pharma, GlaxoSmithKline, Pfizer Inc.

Neurotrophic Keratitis Market to Expand Significantly by 2034, States DelveInsight Report | Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotech

The Key Neurotrophic Keratitis Companies in the market include – Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotechnology Inc., Dompé Farmaceutici S.p.A, Syneos Health, and others.

DelveInsight’s “Neurotrophic Keratitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Neurotrophic Keratitis, historical and forecasted epidemiology as well as the Neurotrophic Keratitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Neurotrophic Keratitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurotrophic Keratitis pipeline products will significantly revolutionize the Neurotrophic Keratitis market dynamics.

To Know in detail about the Neurotrophic Keratitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratitis Market Forecast

Some of the key facts of the Neurotrophic Keratitis Market Report:

The Neurotrophic Keratitis market size was valued ~USD 763 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In January 2025, Provectus Biopharmaceuticals, Inc. (“Provectus”) (OTCQB: PVCT) announced the successful completion of a $3 million seed funding round for VisiRose, Inc., its subsidiary focused on developing innovative ocular therapies. The funding supports preparations for a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding RB-PDAT, a potential treatment for infectious keratitis.
In 2023, France and Italy had the largest market size for Neurotrophic Keratitis in the EU, each reaching nearly USD 5 million, while Germany recorded the smallest market size at approximately USD 2 million.
In 2023, the market size for Neurotrophic Keratitis in Japan was estimated at around USD 1 million.
The total market size for Neurotrophic Keratitis is expected to change in the coming years with the anticipated launch of new therapies, including RGN-259, OC-01, REC-0559, CSB-001, and BRM424, among others.
According to DelveInsight’s analysis, the estimated number of diagnosed prevalent cases of Neurotrophic Keratitis across the 7 major markets (7MM) was approximately 65,000 in 2023.
In 2023, the United States reported the highest number of diagnosed prevalent cases of Neurotrophic Keratitis, with approximately 33,000 cases, and this number is anticipated to increase in the future.
In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of Neurotrophic Keratitis among European countries, with around 8,000 cases, followed by Germany with approximately 6,000 cases. In contrast, Spain had the lowest prevalent population, with about 3,000 cases.
In 2023, Japan recorded nearly 5,000 total diagnosed prevalent cases of Neurotrophic Keratitis, representing about 8% of the total cases across the 7MM.
In the US, individuals in Stage 3 were the most affected by Neurotrophic Keratitis, with approximately 14,000 cases recorded in 2023, according to stage-specific segmentation.
Key Neurotrophic Keratitis Companies: Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotechnology Inc., Dompé Farmaceutici S.p.A, Syneos Health, and others
Key Neurotrophic Keratitis Therapies: OC-01, REC 0559, CSB-001, RGN-259, BRM424, cenegermin-bkbj, Udonitrectag, RGN-259, and others
The Neurotrophic Keratitis epidemiology based on gender analyzed that most of the Neurotrophic Keratitis cases comprise of the female population
The Neurotrophic Keratitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurotrophic Keratitis pipeline products will significantly revolutionize the Neurotrophic Keratitis market dynamics.

Get a Free sample for the Neurotrophic Keratitis Market Report:

https://www.delveinsight.com/report-store/neurotrophic-keratitis-market

Neurotrophic Keratitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neurotrophic Keratitis Epidemiology Segmentation:

The Neurotrophic Keratitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Neurotrophic Keratitis
Prevalent Cases of Neurotrophic Keratitis by severity
Gender-specific Prevalence of Neurotrophic Keratitis
Diagnosed Cases of Episodic and Chronic Neurotrophic Keratitis

Download the report to understand which factors are driving Neurotrophic Keratitis epidemiology trends @ Neurotrophic Keratitis Epidemiology Forecast

Neurotrophic Keratitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurotrophic Keratitis market or expected to get launched during the study period. The analysis covers Neurotrophic Keratitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Neurotrophic Keratitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurotrophic Keratitis Therapies and Key Companies

OC-01: Oyster Point Pharma
REC 0559: Recordati Rare Diseases/MimeTech
CSB-001: Claris Biotherapeutics
RGN-259: ReGenTree
BRM424: BRIM Biotechnology Inc.
cenegermin-bkbj: Dompé Farmaceutici S.p.A
Udonitrectag: Syneos Health
RGN-259: ReGenTree, LLC

Discover more about therapies set to grab major Neurotrophic Keratitis market share @ Neurotrophic Keratitis Treatment Market

Neurotrophic Keratitis Market Strengths

Increasing prevalence of other conditions causes neurotrophic keratitis, thereby increasing NK population.
The development of novel molecules potentially targets epithelial healing and corneal innervation.
Advances in biotechnology, laser and robotic treatment also aid in the treatment of Neurotrophic Keratitis.

Neurotrophic Keratitis Market Opportunities

The recent approval of Oxervate by EMA and priority review designation approved by the USFDA will popularize the utilization of recombinant human nerve growth factors for the treatment of neurotrophic keratitis during the forecast period.
Researchers are increasing their investments to develop and discover drugs that could potentially treat rare eye disease

Scope of the Neurotrophic Keratitis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Neurotrophic Keratitis Companies: Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotechnology Inc., Dompé Farmaceutici S.p.A, Syneos Health, and others
Key Neurotrophic Keratitis Therapies: OC-01, REC 0559, CSB-001, RGN-259, BRM424, cenegermin-bkbj, Udonitrectag, RGN-259, and others
Neurotrophic Keratitis Therapeutic Assessment: Neurotrophic Keratitis current marketed and Neurotrophic Keratitis emerging therapies
Neurotrophic Keratitis Market Dynamics: Neurotrophic Keratitis market drivers and Neurotrophic Keratitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Neurotrophic Keratitis Unmet Needs, KOL’s views, Analyst’s views, Neurotrophic Keratitis Market Access and Reimbursement

To know more about Neurotrophic Keratitis companies working in the treatment market, visit @ Neurotrophic Keratitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Neurotrophic Keratitis Market Report Introduction

2. Executive Summary for Neurotrophic Keratitis

3. SWOT analysis of Neurotrophic Keratitis

4. Neurotrophic Keratitis Patient Share (%) Overview at a Glance

5. Neurotrophic Keratitis Market Overview at a Glance

6. Neurotrophic Keratitis Disease Background and Overview

7. Neurotrophic Keratitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Neurotrophic Keratitis

9. Neurotrophic Keratitis Current Treatment and Medical Practices

10. Neurotrophic Keratitis Unmet Needs

11. Neurotrophic Keratitis Emerging Therapies

12. Neurotrophic Keratitis Market Outlook

13. Country-Wise Neurotrophic Keratitis Market Analysis (2020–2034)

14. Neurotrophic Keratitis Market Access and Reimbursement of Therapies

15. Neurotrophic Keratitis Market Drivers

16. Neurotrophic Keratitis Market Barriers

17. Neurotrophic Keratitis Appendix

18. Neurotrophic Keratitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neurotrophic Keratitis Market to Expand Significantly by 2034, States DelveInsight Report | Oyster Point Pharma, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, ReGenTree, BRIM Biotech

Jean-Pierre Isbouts’ The Fractured Kingdom: Uniting Modern Christianity Through the Historical Jesus Wins Top Prize in International Book Contest

Recognized by the Book Excellence Awards for its outstanding writing, design and overall market appeal, The Fractured Kingdom offers a profound look at the historical Jesus, showing why the universal doctrine of the Lord’s Prayer could be our last hope for forging a more equal, compassionate, and loving society.

Dr. Jean-Pierre Isbouts is a distinguished art historian, bestselling author, and award-winning filmmaker specializing in biblical archaeology, Renaissance Italy, and European history.

A Professor Emeritus at Fielding Graduate University and the Founder and Managing Editor of Fielding University Press, he has authored several acclaimed National Geographic books, including The Biblical World, In the Footsteps of Jesus, The Story of Christianity and The Archaeology of the Bible, which have sold over 2 million copies worldwide. His latest work, The Ultimate Visual History of the World, represents a culmination of his extensive research.

As a Renaissance expert, Dr. Isbouts has authored several books on Leonardo da Vinci, including Mona Lisa and the Elusive Art of Leonardo da Vinci’s Paintings published by Polistampa. Featured on BBC, NBC’s Today, and other major media platforms, he is celebrated for blending scholarly insights with engaging storytelling.

As an accomplished filmmaker, Dr. Isbouts has directed programs featuring Hollywood icons like Charlton Heston and Leonard Nimoy, with broadcasts on ABC, A&E, CNBC, the History Channel, the Hallmark Channel, PBS and other global networks. He has also produced recordings with renowned ensembles such as the Los Angeles Chamber Orchestra.

This one-on-one interview shares Jean-Pierre’s background and experience in writing The Fractured Kingdom: Uniting Modern Christianity Through the Historical Jesus.

Tell us about The Fractured Kingdom: Uniting Modern Christianity Through the Historical Jesus.

In The Fractured Kingdom: Uniting Modern Christianity Through the Historical Jesus, I weave the origin stories of Christianity and the Lord’s Prayer into a reinvigorating and urgent rallying cry for unity in the modern church.

Modern Christianity is undeniably in crisis, torn apart by the very culture wars that dominate our society. But here’s the truth: we’ve been here before. Jesus’s ministry emerged during a time of immense social upheaval in 1st century Galilee—a time not so different from our own. The predatory tax yoke of the Herodian regime, demanding as much as 40% of harvest yields, had led to the wholesale confiscation of farmer’s plots and lands. These were now managed by “stewards” on behalf of rich landowners in Judea and elsewhere, as the Gospels attest. That explains why the Gospels are full of stories of poor and dispossessed people, even though they lived in the most fertile region in the Near East: the Galilee. These catastrophic socio-economic conditions are the backdrop for Jesus’s transformative reimagining of the Torah’s three guiding virtues: social justice, compassion for one another, and an unyielding love for God. He called his program for social and religious renewal among Galileans the “Kingdom of God.” These principles resonated with people desperate for hope and change, and they remain as relevant today as they were then.

In the book, I trace Jesus’s vision for the “Kingdom of God” from its origins to the modern day, showing how understanding the roots of our faith can guide us toward unity. At the heart of this journey lies a powerful antidote to our current divisions: the Our Father. The Lord’s Prayer, the one doctrine Christians universally embrace, offers a roadmap for building a more equal, compassionate, and loving society.

In this way, The Fractured Kingdom is more than a book; it’s an invitation to rediscover the unity and purpose of Christianity. It’s a call to rise above partisanship and division, to embrace the transformative power of love and justice, and to build a church that truly reflects the heart of Jesus’s teachings.

What inspired you to write The Fractured Kingdom: Uniting Modern Christianity Through the Historical Jesus?

I was inspired to write The Fractured Kingdom by a troubling disconnect I see in modern Christianity: politicians and leaders who identify as Christian, yet advocating to reduce or eliminate programs like Medicaid, food stamps, and USAID—lifelines for the poor both at home and abroad. This stance starkly contrasts with the core of Jesus’ teachings, particularly his powerful message in the Sermon on the Mount. Jesus championed compassion, justice, and care for the poor and marginalized, yet these principles seem increasingly absent in public policy.

This book is my response—a call to return to the foundational values of Christianity and to reimagine a faith that prioritizes love and social justice. By exploring the historical Jesus and the profound message of the Lord’s Prayer, I hope to inspire a movement toward unity and a deeper understanding of what it truly means to follow Christ’s example.

How did you feel when you found out you received a Book Excellence Award?

As a best-selling author of National Geographic books on biblical history, receiving a prestigious Book Excellence Award has been an incredible honor, amplifying the impact of my research on the historical Jesus, and offering a powerful platform to highlight how modern Christianity has diverged from the foundational goals of Jesus’s ministry.

The award not only acknowledges the scholarly and spiritual value of my work but also connects me with a global audience eager for thought-provoking insights into faith and history. The Book Excellence Awards celebrate excellence in storytelling, and I’m proud that my work contributes to this legacy, fostering conversations that resonate across faith communities worldwide.

What is one message you would like readers to remember?

At its core, the book invites readers to rediscover the authentic Jesus—stripped of centuries of doctrine and division—and explore his transformative role in modern society. It’s a call to reconnect with the unifying essence of his teachings, offering a renewed perspective for believers across every branch of Christianity, regardless of our political or denominational differences.

Purchasing the Book

The Fractured Kingdom: Uniting Modern Christianity Through the Historical Jesus has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Reviewer Gjeniffer Selig calls it, “a bridge connecting the struggles of the ancient [times] with ours, reminding us of the core values that we should never lose sight of—love, compassion, and justice…a game-changer.” In addition, Dean of the Washington National Cathedral, Randolph M. Hollerith writes, “This is a book for all of us who call ourselves Christians, regardless of what branch of the Church we call home.”

The book is available for sale in eBook, audiobook, and hardcover formats. The audiobook version, narrated by the author himself, provides a unique and personal touch to the listening experience—a rare opportunity for readers to hear the original author bring the words to life. It’s available via Amazon and Audiobooks.com, while the eBook and hardcover editions can be purchased on Amazon, Barnes & Noble, and Apple iBooks. Readers are encouraged to get their copy today: https://www.amazon.com/Fractured-Kingdom-Uniting-Christianity-Historical/dp/164065643X/

For an even deeper exploration, watch the acclaimed 15-episode series, The Search for the Historical Jesus, written and directed by Dr. Isbouts for The Great Courses, now streaming on Amazon Prime Video. Together, the book and series offer a transformative journey into the life and teachings of Jesus: https://thegreatcoursesplus.com

To connect with Jean-Pierre and learn more about his work, visit: https://www.jpisbouts.org/. You can also find him on Facebook and Instagram.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jean-Pierre Isbouts’ The Fractured Kingdom: Uniting Modern Christianity Through the Historical Jesus Wins Top Prize in International Book Contest

Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics

The Key Dry Eye Disease Companies in the market include – Palatin Technologies, Novaliq, mc2 therapeutics, and others.

The Dry Eye Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.

DelveInsight’s “Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Dry Eye Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Dry Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dry Eye Disease Market Forecast

Some of the key facts of the Dry Eye Disease Market Report:

The Dry Eye Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In April 2025, The U.S. Food and Drug Administration (FDA) declined to approve Aldeyra Therapeutics’ dry eye disease treatment, reproxalap, citing insufficient efficacy data. This marks the second rejection, following a similar outcome in 2023. The FDA recommends at least one additional trial to demonstrate the drug’s effectiveness.
In February 2025, Cambium Bio revealed that the FDA has approved the protocol for its Phase III clinical trials of Elate Ocular, aimed at treating moderate to severe dry eye disease.
In January 2025, Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company focused on developing innovative treatments for ophthalmic conditions, has announced the completion of the final patient visit in its Phase III clinical trial of ST-100 (vezocolmitide), its lead therapeutic candidate for Dry Eye Disease.
In December 2024, The FDA issued a nationwide recall of a specific single-use eye drop product. Alcon Laboratories voluntarily recalled one lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, after a customer reported possible fungal contamination in a vial. This recall is limited to the identified lot only.
In August 2024, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company focused on discovering and developing innovative therapies for immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled clinical trial of 0.25% reproxalap ophthalmic solution. This investigational drug candidate aims to treat dry eye disease. Reproxalap showed statistical superiority to the vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), a symptom of dry eye disease accepted by the U.S. Food and Drug Administration (FDA).
In January 2024, Alcon, headquartered in Switzerland, announced the success of its dry eye disease medication AR-15512 in meeting primary endpoints in two Phase III trials, namely COMET-2 and COMET-3. With encouraging results from these trials, the company intends to submit a new drug application (NDA) for AR-15512 to the US Food and Drug Administration (FDA) by mid-2024, as outlined in a press release dated January 9th.
In January 2024, Stuart Therapeutics, a biopharmaceutical firm based in the United States, has initiated a Phase III clinical study for their drug candidate vezocolmitide (ST-100) targeting patients with dry eye disease. This randomized, placebo-controlled trial seeks to assess the effectiveness and safety of a single dose of the ophthalmic solution compared to a placebo. The trial is set to enroll 320 participants.
In 2023, the United States held the largest market share for Dry Eye Disease among the 7MM, with an estimated value of around USD 2,739 million, and this figure is projected to grow further by 2034.
In 2023, the UK had the largest market size for DED among EU countries, reaching USD 232 million, while Spain had the smallest market size, at approximately USD 80 million.
The anticipated launch of new therapies, including RGN-259, Tavilermide (MIM-D3), and AR-15512, is expected to drive changes in the total market size of DED in the coming years.
According to DelveInsight’s assessment, the estimated total number of diagnosed prevalent cases of DED in the 7MM was approximately 54.7 million in 2023.
In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of DED among European countries, with around 6.1 million cases, followed by Germany with approximately 5 million. Spain, meanwhile, had the lowest prevalence, with 2.1 million cases.
The US accounted for the highest percentage of diagnosed prevalent cases of DED among the 7MM countries, representing 41%, while Japan had the lowest, at 19%. This trend is expected to continue throughout the forecast period.
In the US, gender-specific data showed around 9.4 million diagnosed prevalent cases of DED among males and approximately 13 million among females. Projections suggest that by 2034, the prevalence among females will continue to outpace that of males.
In 2023, severity-specific data indicated that mild DED affected the largest group in the US, with around 11.2 million cases, while severe cases numbered 4.5 million. This trend, with mild cases outnumbering severe ones, is expected to persist throughout the forecast period.
Key Dry Eye Disease Companies: Palatin Technologies, Novaliq, mc2 therapeutics, and others
Key Dry Eye Disease Therapies: PL9643, NOV03, CyclASol, MC2-03, and others
The Dry Eye Disease epidemiology based on gender analyzed that females are more affected by Dry Eye Disease than males

Dry Eye Disease Overview

Dry eye disease, also known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS), is a common condition when eyes do not produce enough tears or the tears evaporate too quickly. As tears are essential to lubricate and nourish the eye, the condition leads to eyes drying out and becoming red, swollen, and irritated. Causes for Dry Eye Disease include decreased tear production, excessive tear evaporation, and abnormality in the production of mucus or lipids of the tear layer.

Get a Free sample for the Dry Eye Disease Market Report –

https://www.delveinsight.com/report-store/dry-eye-disease-market-insights

Dry Eye Disease Market

The dynamics of the Dry Eye Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“Of the emerging therapies, MC2-03 (mc2 therapeutics), PL9643 (Palatin Technologies),and many other compelling treatments are expected to change the market scenario of Dry Eye Disease in the upcoming years.”

Dry Eye Disease Epidemiology

Dry Eye Disease Epidemiology Segmentation:

The Dry Eye Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Dry Eye Disease
Prevalent Cases of Dry Eye Disease by severity
Gender-specific Prevalence of Dry Eye Disease
Diagnosed Cases of Episodic and Chronic Dry Eye Disease

Download the report to understand which factors are driving Dry Eye Disease epidemiology trends @ Dry Eye Disease Epidemiological Insights

Dry Eye Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Eye Disease market or expected to get launched during the study period. The analysis covers Dry Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Dry Eye Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Dry Eye Disease treatment, visit @ Dry Eye Disease Medications

Dry Eye Disease Therapies and Key Companies

PL9643: Palatin Technologies
NOV03: Novaliq
CyclASol: Novaliq
MC2-03: mc2 therapeutics

Scope of the Dry Eye Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Dry Eye Disease Companies: Palatin Technologies, Novaliq, mc2 therapeutics, and others
Key Dry Eye Disease Therapies: PL9643, NOV03, CyclASol, MC2-03, and others
Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Dry Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Dry Eye Disease Market Access and Reimbursement

Discover more about therapies set to grab major Dry Eye Disease market share @ Dry Eye Disease Treatment Landscape

Table of Contents

1. Dry Eye Disease Market Report Introduction

2. Executive Summary for Dry Eye Disease

3. SWOT analysis of Dry Eye Disease

4. Dry Eye Disease Patient Share (%) Overview at a Glance

5. Dry Eye Disease Market Overview at a Glance

6. Dry Eye Disease Disease Background and Overview

7. Dry Eye Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Dry Eye Disease

9. Dry Eye Disease Current Treatment and Medical Practices

10. Dry Eye Disease Unmet Needs

11. Dry Eye Disease Emerging Therapies

12. Dry Eye Disease Market Outlook

13. Country-Wise Dry Eye Disease Market Analysis (2020–2034)

14. Dry Eye Disease Market Access and Reimbursement of Therapies

15. Dry Eye Disease Market Drivers

16. Dry Eye Disease Market Barriers

17. Dry Eye Disease Appendix

18. Dry Eye Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics

Astigmatism Market on Track for Major Expansion by 2032, According to DelveInsight | Novartis AG, SEA VISION S.r.l, Johnson & Johnson Services, Inc, Bausch and Lomb

The Key Astigmatism Companies in the market include – Novartis AG, SEA VISION S.r.l, Johnson & Johnson Services, Inc, Bausch and Lomb, CooperVision, Carl Zeiss Meditec AG, Seed Co., Ltd, Essilor Group, and others.

DelveInsight’s “Astigmatism Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Astigmatism, historical and forecasted epidemiology as well as the Astigmatism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Astigmatism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Astigmatism Market Forecast

Some of the key facts of the Astigmatism Market Report:

The Astigmatism market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
Key Astigmatism Companies: Novartis AG, SEA VISION S.r.l, Johnson & Johnson Services, Inc, Bausch and Lomb, CooperVision, Carl Zeiss Meditec AG, Seed Co., Ltd, Essilor Group, and others
The Astigmatism market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Astigmatism pipeline products will significantly revolutionize the Astigmatism market dynamics.

Introduction: Understanding Astigmatism and Its Growing Impact

Astigmatism is a common vision condition caused by an irregularly shaped cornea or lens, which prevents light from focusing properly on the retina. Instead of being round like a basketball, the eye is shaped more like a football, leading to blurred or distorted vision at all distances.

It can occur alongside nearsightedness (myopia) or farsightedness (hyperopia) and may be present from birth or develop over time. Symptoms include blurry vision, eye strain, headaches, and difficulty seeing at night.

Astigmatism is easily diagnosed through an eye exam and can be corrected with glasses, contact lenses, or refractive surgery (like LASIK).

Get a Free sample for the Astigmatism Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/astigmatism-market

Signs and Symptoms of Astigmatism and Associated Risk Factors

Astigmatism manifests with symptoms that can vary in severity. Common signs include blurred or distorted vision, eyestrain, headaches, and difficulties seeing clearly at night. Individuals with astigmatism may also experience squinting or frequent changes in glasses or contact lens prescriptions. While the exact cause of astigmatism is not always clear, certain risk factors contribute to its development. These include genetics, eye injuries, and conditions such as keratoconus. Understanding these risk factors aids in identifying individuals who may be more susceptible to astigmatism and implementing preventive measures.

Diagnosing Astigmatism: A Comprehensive Eye Examination

Diagnosing astigmatism involves a comprehensive eye examination conducted by an optometrist or ophthalmologist. The examination includes a review of medical history, visual acuity tests, and refraction assessment to determine the extent and type of refractive error. Specialized instruments like keratometers and corneal topographers may be used to measure the curvature of the cornea and identify irregularities contributing to astigmatism. Early and accurate diagnosis is crucial for prescribing corrective lenses or exploring other treatment options.

Astigmatism Epidemiology

Astigmatism Epidemiology Segmentation:

The Astigmatism market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Astigmatism
Prevalent Cases of Astigmatism by severity
Gender-specific Prevalence of Astigmatism
Diagnosed Cases of Episodic and Chronic Astigmatism

Download the report to understand which factors are driving Astigmatism epidemiology trends @ Astigmatism Epidemiology Forecast

Evolving Treatment Outlook for Astigmatism

The treatment of astigmatism primarily focuses on correcting the refractive error to improve visual acuity. The main treatment options include eyeglasses and contact lenses, designed to compensate for the irregular corneal shape and provide clear vision. Refractive surgery, such as LASIK or PRK, is another option for those seeking a more permanent solution. These surgical procedures reshape the cornea to enhance its focusing abilities. While not all individuals with astigmatism are candidates for surgery, technological advancements continue to refine these procedures, expanding treatment options for a broader range of patients.

Market Outlook and Growth Factors in Astigmatism Research

The market for astigmatism correction is influenced by technological advancements in eyewear, contact lenses, and refractive surgery. The increasing prevalence of astigmatism worldwide contributes to the market’s growth. Innovative lens designs, materials, and surgical techniques play a role in meeting the diverse needs of individuals with astigmatism. Moreover, a growing emphasis on vision correction and eye care awareness contributes to the demand for effective and accessible treatments. Collaborations between eyewear manufacturers, healthcare providers, and research institutions drive progress in astigmatism management, enhancing the market’s outlook for improved visual outcomes and enhanced quality of life for affected individuals.

Scope of the Astigmatism Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Astigmatism Companies: Novartis AG, SEA VISION S.r.l, Johnson & Johnson Services, Inc, Bausch and Lomb, CooperVision, Carl Zeiss Meditec AG, Seed Co., Ltd, Essilor Group, and others
Astigmatism Therapeutic Assessment: Astigmatism current marketed and Astigmatism emerging therapies
Astigmatism Market Dynamics: Astigmatism market drivers and Astigmatism market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Astigmatism Unmet Needs, KOL’s views, Analyst’s views, Astigmatism Market Access and Reimbursement

To know more about Astigmatism companies working in the treatment market, visit @ Astigmatism Clinical Trials and Therapeutic Assessment

Table of Contents

1. Astigmatism Market Report Introduction

2. Executive Summary for Astigmatism

3. SWOT analysis of Astigmatism

4. Astigmatism Patient Share (%) Overview at a Glance

5. Astigmatism Market Overview at a Glance

6. Astigmatism Disease Background and Overview

7. Astigmatism Epidemiology and Patient Population

8. Country-Specific Patient Population of Astigmatism

9. Astigmatism Current Treatment and Medical Practices

10. Astigmatism Unmet Needs

11. Astigmatism Emerging Therapies

12. Astigmatism Market Outlook

13. Country-Wise Astigmatism Market Analysis (2019–2032)

14. Astigmatism Market Access and Reimbursement of Therapies

15. Astigmatism Market Drivers

16. Astigmatism Market Barriers

17. Astigmatism Appendix

18. Astigmatism Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Astigmatism Market on Track for Major Expansion by 2032, According to DelveInsight | Novartis AG, SEA VISION S.r.l, Johnson & Johnson Services, Inc, Bausch and Lomb

The Door A Jar by Randy Schneider: A New Release Explores Transformation and Ethical Dilemmas

Image of Randy Schneider

Explore the Journey of a Protagonist’s Self-Discovery and Confrontation with Modern Society’s Ethical Dilemmas

Colorado, Denver – April 17, 2025 – The Door A Jar, the latest work from author Randy Schneider, follows the story of a protagonist who seeks to reject his humanity in response to societal disillusionment and personal suffering. Set in a jungle environment, the narrative unfolds as the protagonist embarks on a journey to overcome the limitations of human existence, encountering both physical and spiritual challenges along the way. His path of self-discovery ultimately leads him to a profound transformation, symbolized by his transformation into a jaguar.

The story’s central themes include the nature of reality, self-exploration, and ethical conflict. The protagonist’s desire to escape humanity stems from a growing awareness of the harm caused by societal structures, as well as a deep personal pain that drives his search for something beyond human existence. The book explores the idea that reality is not fixed but is shaped by perception and experience. Through his interactions with various characters, the protagonist comes to understand that all things are interconnected, and the boundaries between life and death are not as clear-cut as they may seem.

A significant portion of the book is devoted to the protagonist’s ethical struggle in the biomedical field. He works for a company involved in the development of drugs intended to treat illnesses, only to uncover that these same drugs are contributing to the illnesses they claim to alleviate. This ethical dilemma is a central point in the narrative, and the protagonist is forced to confront the consequences of his involvement in an industry driven by profit rather than the well-being of others.

The structure of The Door A Jar is non-linear, with the narrative shifting between different perspectives and incorporating dream sequences that challenge traditional storytelling techniques. This approach encourages readers to reflect on the themes of the book in a more personal and introspective manner. Symbolism plays a key role in the story, with natural imagery such as the jungle, ocean, and recurring motifs like jars and doors acting as symbols for the protagonist’s journey and transformation.

The Door A Jar has received positive feedback from readers, with a current rating of 4.5 out of 5 on Amazon. The book is available in four formats: HardCover, Paperback, Kindle Unlimited, and AudioBook. It offers a thought-provoking and reflective narrative that encourages readers to consider the ethical implications of their choices and to examine their own understanding of reality and existence.

DISCLAIMER: This press release is for informational purposes only. It does not constitute professional advice, nor should it be relied upon for any decision-making. While the information herein is believed to be accurate, it is not guaranteed. Randy Schneider and associated parties are not liable for any inaccuracies. Any actions taken based on this press release are at the reader’s discretion.

Purpose of the Press Release

This press release aims to inform readers about Randy Schneider’s The Door A Jar, focusing on its philosophical exploration of human transformation and ethical dilemmas. It seeks to raise awareness of the book’s themes and encourage reflection on its thought-provoking message.

For more information about Randy Schneider or his latest book, The Door A Jar, visit: https://thedoorajar.site.

Media Contact
Company Name: The Door A Jar2
Contact Person: Randy Schneider
Email: Send Email
Phone: (303)-570-02006
Country: United States
Website: https://thedoorajar.site/

Shuman Legal Championing Justice for Injured Workers and Families in Chicago, Illinois

Chicago, IL – April 17, 2025 – Shuman Legal, a leading personal injury law firm with over 35 years of dedicated service, continues to stand out as a trusted advocate for victims of catastrophic workplace accidents. Known for its compassionate approach and relentless pursuit of justice, Shuman Legal delivers life-changing outcomes for families facing the devastating aftermath of serious injuries.

In a recent case that underscores the firm’s unwavering commitment, Shuman Legal successfully represented the family of a FedEx employee who suffered life-altering injuries on the job. While assisting a forklift operator, the worker endured a traumatic incident involving electrocution and physical impact, resulting in severe spinal damage, a torn rotator cuff, impaired speech, and memory loss. The injuries not only altered his physical health but deeply affected his ability to engage with his family and maintain his quality of life.

During this difficult time, medical professionals urged the family to seek legal counsel. Turning to Shuman Legal, they found not only expert attorneys but true partners in their journey toward justice. Marc Shuman and his dedicated team earned the family’s trust by prioritizing their well-being and fighting tirelessly to secure the financial compensation they deserved.

“Marc Shuman and his crew are people that you can trust,” shared the client’s spouse. “He’s an attorney that cares, and he’s not just out there trying to make a buck. They took the extra steps to make sure we were taken care of.”

Shuman Legal’s mission extends beyond the courtroom. The firm views each client as family, recognizing that behind every case is a mother, father, son, or daughter whose life has been irrevocably changed. Their experienced legal team leverages decades of specialized knowledge in workplace injury law to navigate complex claims, ensuring maximum compensation for medical expenses, lost wages, pain, and suffering.

“Our clients are everyday people,” says Marc Shuman, Founder of Shuman Legal. “What we can do as attorneys is get them the financial compensation to help with the pain and suffering they have endured. We will do whatever it takes, because you matter.”

Why Shuman Legal Stands Apart:

Proven Expertise: Over 35 years specializing in workplace accidents and serious injury cases.
Client-Centric Approach: Personalized legal strategies with a focus on empathy and trust.
Relentless Advocacy: Committed to securing full and fair compensation for every client.
Comprehensive Support: Guiding clients through every step of the legal process with care and clarity.

Shuman Legal remains a beacon of hope for injured workers and their families, ensuring their voices are heard and their futures protected. For anyone impacted by a workplace accident, Shuman Legal is the trusted name to turn to.

About Shuman Legal:

Shuman Legal is a premier personal injury law firm based in Chicago, Illinois, with a long-standing reputation for compassionate representation and exceptional results. Specializing in workplace injuries, motor vehicle accidents, and catastrophic injury claims, Shuman Legal empowers victims to reclaim their lives with dignity and justice.

Media Contact
Company Name: Shuman Legal
Contact Person: Marc Shuman
Email: Send Email
Phone: 866-469-9742
Country: United States
Website: https://www.shumanlegal.com/the-5-best-truck-accident-lawyers-in-chicago/

Nova Complex Unveils 3 Billion Renewable Energy and Hyperscale Data Center Project in Brazil

April 17, 2025 – SINGAPORE – Nova Complex, a Singapore infrastructure developer, has revealed plans to invest 3 billion in Brazil to construct an integrated renewable energy and intelligent computing data center complex. The project will adopt a “tri-site deployment” model, combining 1 GW of renewable energy facilities with 800 IT MW of data centers, as part of the company’s global “PowerDataCampus” strategy.

Targeting Brazil’s strategic locations, the initiative aims to optimize regional energy efficiency and accelerate the country’s digital economy. Nova Complex is currently in preliminary discussions with Brazilian authorities and partners regarding site selection, policy frameworks, and implementation.

Bernard Mah, COO of Nova Complex, highlighted Brazil’s vast potential in renewable energy and intelligent computing adoption. “This project will set a regional benchmark for integrating green energy with intelligent computing infrastructure,” he said. The data centers will feature liquid cooling technology, high-density server designs, and smart energy management systems to maximize operational efficiency.

The renewable energy component will utilize Brazil’s solar and wind resources together with hydro power. Nova Complex aims to deliver a model project that fosters local technological advancement and high-value economic opportunities while supporting global climate goals.

Further details on timelines and partnerships will be disclosed as negotiations progress.

Media Contact
Company Name: Nova Complex
Contact Person: Bernard.mah
Email: Send Email
Country: Singapore
Website: https://www.linkedin.com/company/nova-complex